The EDCTP3-funded SNIP-AFRICA project is stepping in to close this knowledge gap. This collaboration between African and European researchers is conducting an adaptive trial, NeoSep1, which will test different antibiotic treatments in areas where multidrug-resistant bacteria are common, to find the most effective treatments for newborn sepsis.
Another study within the project, named PRECISION, will focus on determining the optimal dose of the antibiotic colistin in newborns and children under the age of 2. Colistin is sometimes used as a last-reso
rt option for treating antibiotic-resistant infections, but there is little information about the best doses for this age group.
With this research, SNIP-AFRICA is aiming to reduce newborn deaths by providing evidence for better antibiotic treatments for sepsis. In the future, the findings could help update clinical guidelines for treating newborn sepsis at local, national, and WHO levels, giving these vulnerable babies a better start in life.
